HCM
GILD icon

Highline Capital Management’s Gilead Sciences GILD Stock Holding History

Highline Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-336,000
Closed -$34M – 32
2015
Q4 		$34M Buy
+336,000
New +$35M 1.61% 22

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highline Capital Management's GILD Position: Q1 2016 in Review

Highline Capital Management sold out of Gilead Sciences (GILD) in Q1 2016, closing a stake of 336,000 shares — an estimated $34M sold.

Highline Capital Management first reported a position in GILD in Q4 2015 and held it in 1 quarter. The position peaked at $34M in Q4 2015. 1,629 funds tracked by Wall St. Rank hold GILD as of Q1 2016.

  • Highline Capital Management reported no remaining Gilead Sciences position as of Q1 2016 after selling out during the quarter.
  • Highline Capital Management sold 336,000 Gilead Sciences shares in Q1 2016, an estimated $34M.
  • Highline Capital Management first reported a position in Gilead Sciences in Q4 2015 and held it in 1 quarter.
  • Highline Capital Management's Gilead Sciences position peaked at $34M in Q4 2015.
  • 1,629 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2016.

Based on Highline Capital Management's 13F filing for Q1 2016, filed 16 May 2016.